tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NPCE Stock Latest News

Morning Movers: L3Harris Technologies jumps after DoW investment
The FlyMorning Movers: L3Harris Technologies jumps after DoW investment
1d ago
BK
CAH
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
PremiumThe Fly
NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
2d ago
NPCE
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
PremiumThe Fly
NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M
2d ago
NPCE
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
PremiumThe Fly
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M
2d ago
NPCE
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
PremiumRatings
NeuroPace Initiated With Buy on Breakthrough RNS Label Expansion Opportunity and Strong NAUTILUS Efficacy Data
27d ago
NPCE
NeuroPace files premarket approval supplement application for RNS System
PremiumThe FlyNeuroPace files premarket approval supplement application for RNS System
29d ago
NPCE
NeuroPace price target raised to $22 from $18 at UBS
Premium
The Fly
NeuroPace price target raised to $22 from $18 at UBS
30d ago
NPCE
NeuroPace price target raised to $20 from $18 at JPMorgan
Premium
The Fly
NeuroPace price target raised to $20 from $18 at JPMorgan
1M ago
NPCE
Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
PremiumRatings
Buy Rating Affirmed on Promising NAUTILUS Trial Results and Potential FDA Consideration
1M ago
NPCE
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
PremiumThe Fly
NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting
1M ago
NPCE
NeuroPace announces Medicare reimbursement increases for RNS System
PremiumThe Fly
NeuroPace announces Medicare reimbursement increases for RNS System
2M ago
NPCE
NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
PremiumRatings
NeuroPace’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating
2M ago
NPCE
NeuroPace, Inc. Reports Record Revenue and Growth
PremiumCompany AnnouncementsNeuroPace, Inc. Reports Record Revenue and Growth
2M ago
NPCE
NeuroPace price target raised to $18 from $16 at JPMorgan
Premium
The Fly
NeuroPace price target raised to $18 from $16 at JPMorgan
2M ago
NPCE
NeuroPace Reports Record Revenue and Raises Guidance
Premium
Company Announcements
NeuroPace Reports Record Revenue and Raises Guidance
2M ago
NPCE
NeuroPace reports Q3 EPS (11c), consensus (19c)
PremiumThe Fly
NeuroPace reports Q3 EPS (11c), consensus (19c)
2M ago
NPCE
NPCE Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NPCE Earnings this Week: How Will it Perform?
2M ago
NPCE
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update
PremiumCompany Announcements
Neuropace, Inc. Advances in Treating Lennox-Gastaut Syndrome: A Study Update
3M ago
NPCE
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call
PremiumCompany Announcements
NeuroPace, Inc. Reports Record Revenue and Strong Margins in Q2 2025 Earnings Call
5M ago
NPCE
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome
PremiumCompany AnnouncementsNeuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome
5M ago
NPCE
NeuroPace’s Strategic Advancements and Revenue Growth Underpin Buy Rating Despite Challenges
Premium
Ratings
NeuroPace’s Strategic Advancements and Revenue Growth Underpin Buy Rating Despite Challenges
5M ago
NPCE
NeuroPace Reports Record Revenue and Raises Guidance
Premium
Company Announcements
NeuroPace Reports Record Revenue and Raises Guidance
5M ago
NPCE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >